期刊文献+

1,25(OH)2D3联合顺铂对原代肺腺癌细胞周期及调控因子的影响 被引量:1

Effects of 1,25(OH)2D3 combined with cisplatin on cell cycle and regulatory factors of primary cultured lung adenocarcinoma cells
下载PDF
导出
摘要 目的:探讨1,25(OH)2D3联合顺铂对原代肺腺癌细胞周期及周期相关调控因子的影响。方法:体外培养手术切除的肺腺癌组织细胞,经药物作用后CCK-8法测定细胞抑制率,流式细胞仪检测细胞周期,RT-PCR检测细胞周期调控因子Cyclin D1、CDK4转录水平。结果:不同浓度的1,25(OH)2D3、顺铂单药作用于肺腺癌细胞均有明显的抑制作用,两药联合表现为协同作用,与单药相比,差异有统计学意义(P<0.05)。细胞周期分析显示,经药物联合处理后的肺癌细胞,G0/G1期细胞数增多,S期和G2/M期细胞减少。细胞周期调控因子Cyclin D1、CDK4转录水平均有所降低,差异有统计学意义(P<0.05)。结论:1,25(OH)2D3联合铂类抗癌药物抑制原代肺腺癌细胞的增殖能力、诱导细胞周期阻滞,与下调Cyclin D1和CDK4的表达有关。 Objective:To investigate the effects of 1,25(OH)2D3 combined with cisplatin on cell cycle and cell cycle-related regulatory factors in primary lung adenocarcinoma cells.Methods:Lung adenocarcinoma tissue cells were cultured in vitro.The cell inhibition rate was measured by CCK-8 assay after drug treatment.The cell cycle was detected by flow cytometry.The transcriptional levels of cell cycle regulators Cyclin D1 and CDK4 were detected by RT-PCR.Results:Different concentrations of 1,25(OH)2D3,cisplatin had obvious inhibitory effects on lung cancer cells.The combination of the two drugs showed synergistic effect,and there was significant difference compared with the single drug(P<0.05).Cell cycle analysis showed that G0/G1 cells increased and S and G2/M cells decreased after the lung cancer cells were treated by drug treatment.The transcriptional levels of cell cycle regulators Cyclin D1 and CDK4 were all decreased,and were statistically significant(P<0.05).Conclusion:1,25(OH)2D3 combined with platinum anticancer drugs inhibited the proliferation of primary lung adenocarcinoma cells and induced cell cycle arrest,which was associated with down-regulation of Cyclin D1 and CDK4 expression.
作者 刘洪梅 王希柱 刘静 邱斌 韩素桂 李玉凤 LIU Hongmei;WANG Xizhu;LIU Jing;QIU Bin;HAN Sugui;LI Yufeng(Nuclear Medicine Laboratory,Tangshan People's Hospital,Hebei Tangshan 063000,China;Department of Cardiology,Tangshan People's Hospital,Hebei Tangshan 063000,China;Medical Examination Center,Tangshan People's Hospital,Hebei Tangshan 063000,China;Department of Thoracic Surgery,Tangshan People's Hospital,Hebei Tangshan 063000,China;Tumor Experimental Center,Tangshan People's Hospital,Hebei Tangshan 063000,China)
出处 《现代肿瘤医学》 CAS 2020年第22期3849-3853,共5页 Journal of Modern Oncology
基金 河北省医学科学研究重点课题计划(编号:20171287)。
关键词 1 25(OH)2D3 顺铂 肺腺癌细胞 增殖 细胞周期 1 25(OH)2D3 cisplatin lung adenocarcinoma cells proliferation cell cycle
  • 相关文献

参考文献8

二级参考文献80

  • 1罗世政,冯继锋.紫杉醇联合卡培他滨治疗Ⅳ期肺腺癌的临床疗效研究[J].中国生化药物杂志,2014,34(4):131-133. 被引量:1
  • 2唐健,庄燕妍,黄凤婷,姚和瑞,张世能.TAK1蛋白在胰腺癌中的表达及其临床意义[J].消化肿瘤杂志(电子版),2013,5(1):22-25. 被引量:3
  • 3苗毅,陈建敏.胰腺癌的诊断和外科治疗进展[J].消化肿瘤杂志(电子版),2011,3(4):199-202. 被引量:4
  • 4Anic G M, Weinstein S J, Mondul A M, et al. Serum vitamin D, vita- min D binding protein, and lung cancer survival[J]. Lung Cancer, 2014,86(3):297-303.
  • 5Giovannucci E. The epidemiology of vitamin D and cancer inci- dence and mortality: a review (United States)[J]. Cancer Causes Control,2005,16(2):83-95.
  • 6Chun R F. New perspectives on the vitamin D binding protein[J]. Cell Biochem Funct, 2012,30(6):445-456.
  • 7Weinstein S J, Stolzenberg-Solomon R Z, Kopp W, et al. Impact of circulating vitamin D binding protein levels on the association be-tween 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study[J]. Cancer Res,2012,72(5): 1190-1198.
  • 8Yamamoto N, Homma S. Vitamin D3 binding protein (group-spe- cific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes [J]. Pro Natl Acad Sci U S A, 1991,88(19):8539-8543.
  • 9Nagasawa H, Uto Y, Sasaki H, et al. Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity[J]. Anti- cancer Res,2005,25(6A):3689-3695.
  • 10Weinstein S J, Mondul A M, Kopp W, et al. Circulating 25-hydrox- yvitamin D, vitamin D-binding protein and risk of prostate cancer [J]. I nt J Cancer,2013,132(12):2940-2947.

共引文献65

同被引文献17

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部